Adalimumab biosimilar (Biocad)

阿达木单抗生物类似药 (Biocad)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (Biocad)
Drug Alias Name阿达木单抗生物仿制药(Biocad)BCD-057
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasis
Global Approved IndicationsPsoriasis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryRussian Federation
Original Approved Date2019/03/01
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesBIOCAD JSC
Inactive CompaniesN/A
Active IndicationsPsoriasis
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A